DISCUSSION
NSCLC, tumor
ADVERSE EFFECTS, TUMOR, DISEASE PROGRESSION, NSCLC
This study investigated the feasibility of toripalimab plus anlotinib for patients resistant to EGFR‐TKI. In present study, the intent‐to‐treat (ITT) population did not benefit from the chemo‐free therapies. However, some patients, such as those patients without detectable Chemo‐free therapies such as ICIs combined with antiangiogenic therapy, and ICIs combined with targeted therapy are being explored in EGFR‐TKI‐resistant populations. Current guidelines do not recommend this combination regimen due to the severe adverse effects of ICI combined with targeted therapy, which are difficult for patients to tolerate.The tested regimen was well tolerated in our cohort. There were no new safety issues identified, and AEs were similar to those described in previous clinical studies.In both Impower150 and ORIENT‐31 studies,The effective population of ICIs plus antiangiogenic drugs in patients with advanced EGFR‐TKI‐resistant NSCLC requires further exploration. In In present study, blood ctDNA was detected in baseline and after disease progression in all patients. Several clinical studies have demonstrated that high ctDNA abundance was associated with worse prognosis,Although this was a prospective study, some limitations must be mentioned. First, given the small size of sample, the results need to be carefully understood and validated by large sample‐size studies. Furthermore, considering the difficulty of obtaining tissue samples from patients before enrollment and after disease progression, it was impossible to further detect and explore the changes in the tumor microenvironment.